Observational study of Serum HER2 in HER2 negative advanced gastric cancer treated with capecitabine plus cisplatin(XP)
Not Applicable
- Conditions
- Gastric cancer
- Registration Number
- JPRN-UMIN000006442
- Lead Sponsor
- Sapporo Medical University 1st department of Internal Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1)Other malignancies within the last 2 years, except for carcinoma in situ or basal cell carcinoma. 2)Positive serum pregnancy test in women of childbearing, or lactating women. 3)History of psychiatric disability judged by investigator to be clinically significant, precluding informed consent. 4)Serious intercurrent infections. 5)Patients whom physician determines as inappropriate
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method